Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

David Correa Allied Market Research + + 1 800-792-5285 email us here Visit us on social media: Facebook X LinkedIn YouTube ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Q. I have a leaky heart valve that may need surgery down the road. Can you tell me about heart-valve surgery in one of your columns? A. First, let’s explain briefly how the heart works.

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to ...

Edwards Lifesciences (NYSE: EW) shares got a boost after hours today on fourth-quarter results that came in ahead of the consensus forecast.

pathophysiology and outcomes of mixed aortic valve disease (MAVD), which refers to combined aortic stenosis and aortic regurgitation. To assess the haemodynamic and clinical severity of MAVD using an ...

February is American Heart Month, a highlight of which is Wear Red Day, which aims to raise awareness about heart disease in ...

Over the last decade, Nairobi West Hospital has been pioneering innovative heart failure treatment strategies that have ...